Dinaciclib

Generic Name: Dinaciclib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₈N_₆O_₂

CAS Number: 779353-01-4

Unique Ingredient Identifier: 4V8ECV0NBQ

Background: Dinaciclib has been used in trials studying the treatment of rrMM, rrCLL, rrDLBCL, Solid Tumors, and Solid Neoplasm, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Pancreatic Adenocarcinoma
Recurrent Pancreatic Carcinoma
Unresectable Pancreatic Carcinoma
Stage III Pancreatic Cancer AJCC v6 and v7
Stage IV Pancreatic Cancer AJCC v6 and v7

Interventions: Drug: Akt Inhibitor MK2206
Drug: Dinaciclib
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2013-02-04

Last Posted Date: 2017-08-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT01783171

Locations: 🇺🇸
University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 2 locations

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase 1

Completed

Conditions: Recurrent Plasma Cell Myeloma

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: Dinaciclib
Other: Laboratory Biomarker Analysis

First Posted Date: 2012-10-22

Last Posted Date: 2018-05-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT01711528

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 3 locations

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

Phase 1

Completed

Conditions: Estrogen Receptor Negative
HER2/Neu Negative
Recurrent Breast Carcinoma
Triple-Negative Breast Carcinoma
Male Breast Carcinoma
Progesterone Receptor Negative
Stage IV Breast Cancer AJCC v6 and v7

Interventions: Drug: Dinaciclib
Drug: Epirubicin Hydrochloride
Other: Laboratory Biomarker Analysis

First Posted Date: 2012-06-20

Last Posted Date: 2018-03-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT01624441

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Phase 1

Completed

Conditions: Recurrent Small Lymphocytic Lymphoma
Prolymphocytic Leukemia
Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: Dinaciclib
Other: Laboratory Biomarker Analysis
Biological: Ofatumumab
Other: Pharmacological Study

First Posted Date: 2012-01-23

Last Posted Date: 2018-03-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT01515176

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm

Interventions: Drug: Dinaciclib
Drug: Veliparib

First Posted Date: 2011-09-14

Last Posted Date: 2024-08-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 121

Registration Number: NCT01434316

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Refractory Multiple Myeloma

Interventions: Drug: dinaciclib
Other: laboratory biomarker analysis

First Posted Date: 2010-03-31

Last Posted Date: 2014-06-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT01096342

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇸🇬
National University Hospital, Singapore, Singapore
🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

and more 3 locations

Dinaciclib in Treating Patients With Stage III-IV Melanoma

Phase 1

Terminated

Conditions: Stage IIIB Melanoma
Stage IV Melanoma
Stage IIIC Melanoma

Interventions: Drug: dinaciclib
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2009-12-04

Last Posted Date: 2017-04-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT01026324

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Dinaciclib in Treating Patients With Stage IV Melanoma

Phase 2

Active, not recruiting

Conditions: Acral Lentiginous Melanoma
Cutaneous Nodular Melanoma
Lentigo Maligna Melanoma
Low-CSD Melanoma
Mucosal Melanoma
Recurrent Melanoma
Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions: Drug: Dinaciclib

First Posted Date: 2009-07-13

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 72

Registration Number: NCT00937937

Locations: 🇺🇸
Cancer Center of Kansas - Chanute, Chanute, Kansas, United States
🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸
Logan Health Medical Center, Kalispell, Montana, United States

and more 187 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy